ZUIG
15F, Tower B UDC Time Building, 8 Xinye Road, Hangzhou, Zhejiang, China
Overview
Zhejiang United Investment Group ("ZUIG") is a major investment platform established in April, 2015 by eight leading private enterprises and ICBC Credit Suisse Asset Management, the first of its kind in Zhejiang, drawing on the guidance and support from the Zhejiang Federation of Industry and Commerce, Zhejiang Provincial Financial Service Office, and Zhejiang Branch, Industrial and Commercial Bank of China. ZUIG's nine founding shareholders include CHINT Group, FuTong Group, GreatStar Holding Group, Wolong Holding Group, Wanfeng Auto Holding Group, Aux Group, Sunon Group, Hangzhou Jinjiang Group, and ICBC Credit Suisse Asset Management, with sector verticals covering smart appliances, renewable energy, communications, machinery manufacturing, auto parts, furniture, home appliances, environmental protection, healthcare, and financial services. Initial registered capital amounts to RMB 5 billion, and is targeted to increase gradually to RMB 30 billion throughout the next few years. ZUIG's investment priorities encompass fields such as advanced manufacturing, high-end equipment, renewable energy, environmental, consumer goods, and healthcare, employing an innovative investment approach combining direct project investment, fund of funds, structured product and market oriented fund. Building on our strong industry know-how, financial prowess and managerial expertise, ZUIG will actively participate in strategic M&As, restructuring and reorganization transactions involving state-owned-enterprises, and investments in strategic emerging industries, enabling it to establish itself as a top asset management company.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 5
Investment portfolio
- Drug Farm
Participated · Equity · Feb 2021
Drug Farm leverages proprietary platforms—IDInVivo+ (which integrates genetics and AI to identify and validate targets in living systems) and MedChem5 (used to advance first-in-class candidates)—to discover and progress drug candidates. The company is developing treatments across rare disease, cardiovascular, kidney, metabolic, autoimmune, and infectious disease indications. Its lead program, DF-003, is a first-in-class ALPK1 inhibitor that has shown clinical improvement in an ongoing Phase 1b study for ROSAH syndrome and is positioned to enter a Phase 3 trial; DF-003 has received multiple FDA designations including Fast Track and Orphan Drug. Another key program, DF-006, is an orally administered ALPK1 agonist immunomodulator that completed single and multiple ascending dose evaluations in healthy volunteers and in virologically suppressed HBeAg-negative chronic hepatitis B patients, showing encouraging anti-HBV activity. Drug Farm has entered a clinical collaboration with Xiamen Amoytop Biotech to develop DF-006 for hepatitis B and hepatocellular carcinoma. The recent $55 million Series D first closing provides capital to advance pivotal trials, global development, regulatory activities, and R&D expansion.
- Zero Zero Robotics
Participated · Series A · Apr 2016
Zero Zero Robotics is a China-based company that has been working on self-flying drone technology since 2014 and employs roughly 70 people. Its first product, Hover, is a lightweight (240g) self-flying camera drone designed for easy close-up video capture without manual piloting. Hover packs a 13MP sensor capable of 4K video and uses custom electronic image stabilization instead of a mechanical gimbal. The drone includes preprogrammed features such as hover-in-place, face and body recognition follow modes, and 360-degree pano recording to simplify use for novices. The company says it will replicate Hover’s self-flying capabilities in future products and plans to ship Hover this summer. Zero Zero has raised $25M in funding to support the product launch and development, composed mainly of a $23M Series A.
Team
Chen Geng
President ,CEO & Board Director
LinkedInZhou Guanxin
Executive Vice President
Wu Zhen
Managing Partner
Yuan Huagang
Managing Partner